Vor Bio (VOR, Financial) has finalized a securities purchase agreement leading to a private equity financing round, projected to generate approximately $175 million in gross proceeds before expenses. According to the agreement terms, Vor Bio will issue prefunded warrants for a total of 700 million common stock shares, priced at $0.25 per warrant upon the PIPE's closure.
The financing round involved esteemed investors such as existing stakeholder RA Capital Management, along with Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners, and NEXTBio. The company plans to allocate the net proceeds towards progressing its clinical program as well as general corporate objectives.
The private placement is slated to close on June 27, 2025, contingent on customary closing conditions. The warrants carry an exercise price of $0.0001 per share and will be exercisable once Vor Bio's stockholders approve the underlying share issuance. A special stockholder meeting will be organized to seek approval for this and other related matters.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Vor Biopharma Inc (VOR, Financial) is $0.32 with a high estimate of $0.40 and a low estimate of $0.25. The average target implies an downside of 42.88% from the current price of $0.55. More detailed estimate data can be found on the Vor Biopharma Inc (VOR) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Vor Biopharma Inc's (VOR, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
